Shares of Recursion Pharmaceuticals Slide After 1Q Loss

Dow Jones

May 06

By Roshan Fernandez

Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss.

Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date.

The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier.

Analysts polled by FactSet were expecting a loss of 52 cents a share.

Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million.

The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia.

Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024.

Write to Roshan Fernandez at roshan.fernandez@wsj.com

(END) Dow Jones Newswires

May 05, 2025 12:21 ET (16:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533371155"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533371155\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533371155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-06 00:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533371155","market":"other","top_or_hot":-1,"title":"Shares of Recursion Pharmaceuticals Slide After 1Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. \n</p>\n<p>\n  Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date. \n</p>\n<p>\n  The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier. \n</p>\n<p>\n  Analysts polled by FactSet were expecting a loss of 52 cents a share. \n</p>\n<p>\n  Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million. \n</p>\n<p>\n  The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia. \n</p>\n<p>\n  Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2025 12:21 ET (16:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shares of Recursion Pharmaceuticals Slide After 1Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShares of Recursion Pharmaceuticals Slide After 1Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-06 00:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. \n</p>\n<p>\n  Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date. \n</p>\n<p>\n  The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier. \n</p>\n<p>\n  Analysts polled by FactSet were expecting a loss of 52 cents a share. \n</p>\n<p>\n  Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million. \n</p>\n<p>\n  The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia. \n</p>\n<p>\n  Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 05, 2025 12:21 ET (16:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2533371155","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533371155","pubTimestamp":1746462060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss.Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date.The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier.Analysts polled by FactSet were expecting a loss of 52 cents a share.Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million.The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia.Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4139":"生物科技","RXRX":"Recursion Pharmaceuticals, Inc.","BK4611":"AI医疗","BK4609":"英伟达持仓股","BK4539":"次新股"},"translate_title":"Recursion Pharmaceuticals股价在第一季度亏损后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"By Roshan Fernandez \n\n\n \n\n\n  Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss. \n\n\n  Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date. \n\n\n  The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier. \n\n\n  Analysts polled by FactSet were expecting a loss of 52 cents a share. \n\n\n  Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million. \n\n\n  The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia. \n\n\n  Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024. \n\n\n \n\n\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2025 12:21 ET (16:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}